EUVIMEDEUVIMED entdecken
Kohortenstudie

Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates

Vivek Mundada iD, Omendra Narayan, Siddharth Arora, Nidhi Beri, Rania Abusamra, Deepak Mullasery, Deepak Parashar

Muscle & Nerve · 2024

DOI: 10.1002/mus.28222 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Vivek Mundada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Neuroscience, Aster DM Healthcare, Medcare Women and Children Hospital, Dubai, UAE. Hauptthemen laut MEDLINE: Genetic Therapy, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Spinal muscular atrophy (SMA) manifests with progressive motor neuron degeneration, leading to muscle weakness. Onasemnogene abeparvovec is a US Food and Drug Administration‐approved gene replacement therapy for SMA. This study aimed to present short‐term data of children in the United Arab Emirates (UAE) treated with onasemnogene abeparvovec, particularly in the context of children requiring invasive ventilatory support via tracheostomy.

Methods

A retrospective analysis was performed on 60 children who received onasemnogene abeparvovec. All these children received corticosteroids. They were followed up for up to 3 months. Motor function assessments were performed before and after the gene therapy. Comprehensive clinical evaluations, including pulmonary functions, were performed at baseline and the 3‐month mark.

Results

Forty‐three percent were male, and the mean age at the time of infusion was 29.6 months (SD ± 17.2). The mean weight was 10.1 kg (SD 2.6). All children demonstrated marked improvements in motor function within 3 months of gene therapy administration. No adverse effects attributable to corticosteroid therapy were observed. Positive clinical outcomes, including increased ventilator‐free intervals, reduced antibiotic dependency, and fewer hospital admissions, were reported among children with invasive ventilation via tracheostomy.

Discussion

This study demonstrates the favorable tolerability and promising responses to onasemnogene abeparvovec in invasively ventilated pediatric patients. Early improvements in motor function, as observed within 3 months post‐treatment, suggest its potential as a viable therapeutic option for this vulnerable patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyBiological ProductsHumansMaleUnited Arab EmiratesFemaleChild, PreschoolInfantRetrospective StudiesCohort StudiesMuscular Atrophy, SpinalChildTreatment OutcomeRecombinant Fusion Proteins

Stichwörter der Autor:innen

onasemnogene abeparvovecprednisolonespinal muscular atrophytracheostomy

Substanzen

ZolgensmaBiological ProductsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Paediatric Neuroscience, Aster DM Healthcare, Medcare Women and Children Hospital, Dubai, UAE.
  • Department of Paediatric Pulmonology, American Hospital, Dubai, UAE.
  • Department of Paediatrics Neurodisability, Aster DM Healthcare, Medcare Women and Children Hospital, Dubai, UAE.
  • Department of Paediatric Pulmonology, Mediclinic City Hospital, Dubai, UAE.
  • Department of Paediatric Physiotherapy, Medcare Physiotherapy and Rehabilitation Centre, Dubai, UAE.
  • Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.

ORCID-Profile: Vivek Mundada

Zitieren

APA

Mundada, V., Narayan, O., Arora, S., Beri, N., Abusamra, R., Mullasery, D., & Parashar, D. (2024). Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates. Muscle & Nerve. https://doi.org/10.1002/mus.28222

Vancouver

Mundada V, Narayan O, Arora S, Beri N, Abusamra R, Mullasery D, et al. Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates. Muscle & Nerve. 2024. doi:10.1002/mus.28222

BibTeX
@article{Mundada2024,
  author = {Mundada, Vivek and Narayan, Omendra and Arora, Siddharth and Beri, Nidhi and Abusamra, Rania and Mullasery, Deepak and Parashar, Deepak},
  title = {Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates},
  journal = {Muscle & Nerve},
  year = {2024},
  doi = {10.1002/mus.28222}
}
Kostenlos starten →